The pathological sections from the mice treated with MSC-FGF21+GLP1 showed that the amount of blank area decreased, indicating that the degree of hepatic steatosis was reduced and that the treatment was effective (Fig. 5a). This evidence concerns the gene FGF21 and fatty liver disease.